| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0748-7983(98)93896-3 |
| P698 | PubMed publication ID | 9870738 |
| P2093 | author name string | Hoekstra HJ | |
| van der Graaf WT | |||
| van Horn JR | |||
| Schraffordt Koops H | |||
| Ham SJ | |||
| Postma L | |||
| P2860 | cites work | Interaction between the retinoblastoma protein and the oncoprotein MDM2 | Q24323385 |
| Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line | Q24338329 | ||
| Amplification of a gene encoding a p53-associated protein in human sarcomas | Q28270924 | ||
| The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation | Q28280958 | ||
| p53 mutations in human cancers | Q28302973 | ||
| p53-dependent apoptosis modulates the cytotoxicity of anticancer agents | Q29615031 | ||
| Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 | Q29615851 | ||
| Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours | Q29618396 | ||
| Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms | Q29618586 | ||
| A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma | Q29618817 | ||
| p53 is required for radiation-induced apoptosis in mouse thymocytes | Q29620281 | ||
| Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 | Q29622924 | ||
| Bone cancers | Q33278496 | ||
| Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study | Q33330889 | ||
| Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: phase II trial of the European Osteosarcoma Intergroup | Q33487964 | ||
| Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. | Q34339088 | ||
| Multidrug resistance: molecular mechanisms and clinical relevance | Q34436952 | ||
| A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup | Q34540542 | ||
| Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. | Q34559072 | ||
| Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience | Q67530667 | ||
| Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study | Q67701425 | ||
| Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experience | Q67726432 | ||
| Increased survival, limb preservation, and prognostic factors for osteosarcoma | Q67919651 | ||
| Clinical importance of near-diploid tumor stem lines in patients with osteosarcoma of an extremity | Q67921195 | ||
| Etoposide, cyclophosphamide, cisplatin, and doxorubicin as neoadjuvant chemotherapy for osteosarcoma | Q68003730 | ||
| Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms | Q68097060 | ||
| Preoperative chemotherapy for osteosarcoma with intravenous adriamycin and intra-arterial cis-platinum | Q68192372 | ||
| Tumor suppressor genes | Q68264184 | ||
| P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil | Q68289591 | ||
| Influence of chemotherapy on perioperative complications in limb salvage surgery for bone tumors | Q68451093 | ||
| Resection of Malignant Bone Tumors of the Pelvic Girdle Without Extremity Amputation | Q68500464 | ||
| The relationship of various aspects of surgical management to outcome in childhood nonmetastatic osteosarcoma: a report from the Childrens Cancer Study Group | Q68520236 | ||
| Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience | Q68588454 | ||
| Osteosarcoma: MR imaging after preoperative chemotherapy | Q68695611 | ||
| Low-grade intraosseous osteosarcoma | Q68715189 | ||
| Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/the Children's Hospital--study III | Q68771157 | ||
| Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarter | Q68780653 | ||
| The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity | Q68879882 | ||
| Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years | Q68954562 | ||
| Osteosarcoma.An assessment of management with particular reference to primary irradiation and selective delayed amputation | Q69001751 | ||
| Medullary extension of osteosarcoma.Implications for rational therapy | Q69040248 | ||
| Amputation and Adriamycin in Primary Osteosarcoma | Q69055787 | ||
| Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer | Q69094815 | ||
| Recent advances in the chemotherapy of metastatic osteogenic sarcoma | Q69102684 | ||
| Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy | Q69111750 | ||
| Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma | Q69356736 | ||
| Can historical controls be used in current clinical trials in osteosarcoma? Analysis of prognostic factors | Q72636711 | ||
| Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy | Q72880116 | ||
| Modulation of multidrug resistance: at the threshold | Q72888545 | ||
| Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions | Q73016370 | ||
| The place of external irradiation in the treatment of osteogenic sarcoma | Q73101051 | ||
| The role of allografts in tumour surgery | Q73125941 | ||
| p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate | Q73265770 | ||
| Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis | Q73434458 | ||
| Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma | Q73807203 | ||
| P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy | Q73924977 | ||
| Expression of transforming growth factor-beta (TGF-beta) isoforms in osteosarcomas: TGF-beta3 is related to disease progression | Q73954434 | ||
| External and internal hemipelvectomy for sarcomas of the pelvic girdle: consequences of limb-salvage treatment | Q74250852 | ||
| L-PHENYLALANINE MUSTARD AS A TREATMENT FOR METASTATIC OSTEOGENIC SARCOMA IN CHILDREN | Q76499491 | ||
| OSTEOSARCOMA. A STUDY OF THE VALUE OF PREOPERATIVE MEGAVOLTAGE RADIOTHERAPY | Q76787981 | ||
| Skeletal sarcomata and giant-cell tumour | Q78691448 | ||
| Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration | Q34563351 | ||
| Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma | Q34613462 | ||
| Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response | Q34659387 | ||
| Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study | Q34707770 | ||
| Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup | Q34743096 | ||
| Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs | Q35253417 | ||
| Malignant transformation in Paget disease of bone. | Q35544000 | ||
| p53 function and dysfunction | Q35721291 | ||
| A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group | Q35977382 | ||
| The p53 tumour suppressor gene | Q37751892 | ||
| Trends and variability in survival among patients with osteosarcoma: a 7-year update | Q38520992 | ||
| The Istituto Rizzoli experience with small cell osteosarcoma. | Q38722433 | ||
| The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli | Q39240570 | ||
| Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy | Q39340821 | ||
| Letter: Late metastases in osteosarcoma | Q39373254 | ||
| Combination chemotherapy with bleomycin, cyclophosphamide and dactinomycin for the treatment of osteogenic sarcoma | Q39465516 | ||
| Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery | Q39553218 | ||
| DNA cytometry of osteosarcoma | Q39553931 | ||
| Clinical implications of tumor-cell heterogeneity | Q39732423 | ||
| Thoracotomy for pulmonary metastatic osteosarcoma. An analysis of prognostic indicators of survival | Q39754257 | ||
| Multiple-drug resistance in human cancer | Q39765553 | ||
| Ifosfamide--pharmacology, safety and therapeutic potential | Q39827086 | ||
| Osteosarcoma: fifteen years later | Q39835579 | ||
| The therapy of osteogenic sarcoma: Current status and thoughts for the future | Q39921246 | ||
| Osteosarcoma of the long bones. Clinical observations and experiences in the Netherlands | Q40561862 | ||
| Massive allografts in the treatment of osteosarcoma and Ewing sarcoma in children and adolescents | Q40570078 | ||
| Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma.Pre-surgical treatment of primary tumor and of overt pulmonary metastases | Q40640605 | ||
| Adjuvant multiple drug chemotherapy for osteosarcoma of the extremity | Q40640612 | ||
| Chemotherapy and thoractomy for metastatic osteogenic sarcoma.A model for adjuvant chemotherapy and the rationale for the timing of thoracic surgery | Q40673591 | ||
| Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases | Q40701638 | ||
| Prognostic factors in osteosarcoma: a critical review. | Q40717698 | ||
| Response of osteogenic sarcoma to the combination of etoposide and cyclophosphamide as neoadjuvant chemotherapy | Q40764963 | ||
| Tumor size and prognosis in aggressively treated osteosarcoma | Q40982147 | ||
| The art of limb salvage in musculoskeletal oncology | Q41122556 | ||
| Influence of Doxorubicin Dose Intensity on Response and Outcome for Patients With Osteogenic Sarcoma and Ewing's Sarcoma | Q41140343 | ||
| Insulinlike growth factor I: a potent mitogen for human osteogenic sarcoma | Q41198982 | ||
| Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein | Q41578162 | ||
| Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome | Q41816411 | ||
| p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas | Q42281236 | ||
| Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies | Q42812351 | ||
| Prognostication including DNA analysis in osteosarcoma | Q43499961 | ||
| Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma | Q43530470 | ||
| Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood | Q43675408 | ||
| Inhibition of Metastatic Behavior of Murine Osteosarcoma by Hypophysectomy | Q43901392 | ||
| Editorial: A giant step forward - if.... | Q44019861 | ||
| Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial | Q44078017 | ||
| Chemotherapy,en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma | Q44103159 | ||
| A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study | Q44158194 | ||
| Limb salvage for skeletal and soft tissue sarcomas multidisciplinary preoperative therapy | Q44483340 | ||
| The surgical management of primary osteosarcoma | Q44533081 | ||
| Aggressive thoracotomy for pulmonary metastatic osteogenic sarcoma in children and young adolescents | Q44552572 | ||
| Results of multiple pulmonary resections for metastatic osteogenic sarcoma after two decades | Q44571122 | ||
| Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis | Q44684939 | ||
| Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma | Q44949974 | ||
| Adjuvant adriamycin and cisplatin in newly diagnosed, nonmetastatic osteosarcoma of the extremity | Q45052697 | ||
| The implications of "skip" metastases in osteosarcoma | Q51662406 | ||
| Methotrexate pharmacokinetics and prognosis in osteosarcoma. | Q52374633 | ||
| Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. | Q52501703 | ||
| Osteosarcoma: chemotherapy-induced changes at MR imaging. | Q52861262 | ||
| Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). | Q52865501 | ||
| Limb salvage surgery for primary bone sarcoma of the lower extremities: long-term consequences of endoprosthetic reconstructions. | Q53570772 | ||
| Bone Sarcoma: Treatment by Irradiation, Amputation, or a Combination of the Two | Q53817006 | ||
| High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma | Q54091788 | ||
| Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON | Q54265673 | ||
| The p53 tumor-suppressor gene | Q54269467 | ||
| Mechanism of multidrug resistance in human tumour cell lines and complete reversion of cellular resistance. | Q54281116 | ||
| P-Glycoprotein Expression as a Predictor of the Outcome of Therapy for Neuroblastoma | Q54283001 | ||
| Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. | Q54356862 | ||
| Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial | Q54384006 | ||
| Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukaemia. | Q54413132 | ||
| Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. | Q54454532 | ||
| Prognostic factors in osteosarcomas. A regression analysis | Q57618774 | ||
| Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance | Q59050857 | ||
| Life (and death) in a malignant tumour | Q59098941 | ||
| The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma | Q66875216 | ||
| Role of therapeutic radiology in cancer of bone | Q66891932 | ||
| Preoperative irradiation for osteogenic sarcoma | Q67243377 | ||
| Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy | Q67490263 | ||
| Resection of pulmonary metastases in osteosarcoma. A retrospective analysis of 44 patients | Q69609387 | ||
| Small cell osteosarcoma. A clinicopathologic study of 27 cases | Q69777153 | ||
| Postradiation osteogenic sarcoma of bone and soft tissues. A clinicopathologic study of 66 patients | Q69833034 | ||
| Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients | Q69833036 | ||
| Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma | Q69871128 | ||
| P-glycoprotein in human sarcoma: evidence for multidrug resistance | Q69904603 | ||
| Historical note on bone and soft tissue sarcoma | Q69923025 | ||
| Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study | Q70222884 | ||
| The contribution of salvage surgery to the management of childhood osteosarcoma | Q70233033 | ||
| A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma | Q70325913 | ||
| Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation. French Bone Tumor Study Group | Q70378715 | ||
| Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone | Q70524574 | ||
| Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy | Q70566496 | ||
| Osteogenic sarcoma with clinically detectable metastasis at initial presentation | Q70590738 | ||
| Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen | Q70770968 | ||
| Skip metastases in osteosarcoma: recent experience | Q70899424 | ||
| Analysis of P-glycoprotein expression in osteosarcoma | Q70901532 | ||
| Osteogenic sarcoma associated with Paget's disease of bone. A clinicopathologic study of 65 patients | Q70914077 | ||
| Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy | Q70930286 | ||
| An Analysis of Thirty Patients Surviving Longer than Ten Years after Treatment for Osteogenic Sarcoma | Q70931260 | ||
| High-grade surface osteosarcomas | Q70932706 | ||
| Changing metastatic patterns of osteosarcoma | Q70960372 | ||
| Long-term results of allograft replacement in the management of bone tumors | Q70987871 | ||
| Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma | Q71093029 | ||
| Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome | Q71523309 | ||
| P-glycoprotein--a marker of cancer-cell behavior | Q71523328 | ||
| Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells | Q71635627 | ||
| Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature | Q71778482 | ||
| MDM2 gene amplification in bone and soft‐tissue tumors: Association with tumor progression in differentiated adipose‐tissue tumors | Q71820198 | ||
| Limb salvage for neoplasms of the shoulder girdle. Intermediate reconstructive and functional results | Q71952715 | ||
| Multiple-drug chemotherapy for the primary treatment of osteosarcoma of the extremities | Q71974270 | ||
| Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group | Q71975310 | ||
| Local recurrence after amputation for osteosarcoma | Q71976446 | ||
| Prosthetic survival and clinical results with use of large-segment replacements in the treatment of high-grade bone sarcomas | Q71977495 | ||
| En bloc resections for osteogenic sarcoma | Q71980187 | ||
| Adjuvant adriamycin and cis-diamminedichloroplatinum (cis-platinum) in primary osteosarcoma | Q71995488 | ||
| Development and test of an extendable endoprosthesis for bone reconstruction in the leg | Q72107520 | ||
| Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial | Q72182720 | ||
| Parosteal osteosarcoma. A clinicopathological study | Q72287921 | ||
| Treatment of high-grade bone sarcomas with neoadjuvant chemotherapy: the utility of sequential color Doppler sonography in predicting histopathologic response | Q72324083 | ||
| Can MRI predict the histopathological response in patients with osteosarcoma after the first cycle of chemotherapy? | Q72331601 | ||
| Changes in tumor perfusion induced by chemotherapy in bone sarcomas: color Doppler flow imaging compared with contrast-enhanced MR imaging and three-phase bone scintigraphy | Q72352785 | ||
| Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma | Q72377569 | ||
| Clinicopathologic correlations and short-term prognosis in musculoskeletal sarcoma with c-myc oncogene amplification | Q72448051 | ||
| Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival | Q72532464 | ||
| Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin | Q72613107 | ||
| Fractures in large-segment allografts | Q72619423 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 584-600 | |
| P577 | publication date | 1998-12-01 | |
| P1433 | published in | European Journal of Surgical Oncology | Q2345728 |
| P1476 | title | Historical, current and future aspects of osteosarcoma treatment | |
| P478 | volume | 24 |
| Q36211281 | Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma |
| Q39540587 | Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines |
| Q36464735 | Association of MMP-2 expression and prognosis in osteosarcoma patients |
| Q36416575 | CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study |
| Q53248873 | High expression of MACC1 predicts poor prognosis in patients with osteosarcoma. |
| Q35834339 | High serum alkaline phosphatase cooperating with MMP-9 predicts metastasis and poor prognosis in patients with primary osteosarcoma in Southern China |
| Q38612502 | Hyperthermic Isolated Limb Perfusion with TNF alpha and Cisplatin in the Treatment of Osteosarcoma of the Extremities: A Feasibility Study in Healthy Dogs |
| Q35894890 | Identification of a novel molecular probe for recognition of human osteosarcoma cell using the cell-SELEX method |
| Q41611452 | Inhibitory effects of low-intensity pulsed ultrasound sonication on the proliferation of osteosarcoma cells |
| Q39175955 | Knockdown of AXL receptor tyrosine kinase in osteosarcoma cells leads to decreased proliferation and increased apoptosis |
| Q39069991 | MACC1 is involved in the regulation of proliferation, colony formation, invasion ability, cell cycle distribution, apoptosis and tumorigenicity by altering Akt signaling pathway in human osteosarcoma |
| Q48162996 | Metastatic osteosarcoma causing intussusception |
| Q48698191 | Metastatic osteosarcoma to the brain in adult patient |
| Q92608516 | Monocarboxylate Transporter 4 (MCT4) Overexpression Is Correlated with Poor Prognosis of Osteosarcoma |
| Q39270813 | Perifosine induces cell apoptosis in human osteosarcoma cells: new implication for osteosarcoma therapy? |
| Q44660842 | Role of integrin-linked kinase in osteosarcoma progression. |
| Q28537665 | Salinomycin activates AMP-activated protein kinase-dependent autophagy in cultured osteoblastoma cells: a negative regulator against cell apoptosis |
| Q39036074 | Sulforaphane induces DNA damage and mitotic abnormalities in human osteosarcoma MG-63 cells: correlation with cell cycle arrest and apoptosis |
| Q57494129 | Transglutaminase-2 promotes metastatic and stem-like phenotypes in osteosarcoma |
Search more.